New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
16:07 EDTSSHSunshine Heart initiated with an Overweight at Piper Jaffray
Target $10.
News For SSH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
05:42 EDTSSHSunshine Heart provides update on C-Pulse technology
Sunshine Heart announced an update on its next generation, fully implantable version of the company's flagship C-Pulse technology. Sunshine Heart reports that it will commence a first-in-human study using the novel transcutaneous energy transmission system and a new smaller implantable pump in Q3 2016. The study will initially enroll patients at hospitals outside the U.S., and will target patients suffering from advanced Class III/IV heart failure, similar to the patient population of Sunshine Heart's current ongoing COUNTER HF Study. Feasibility of implant, safety and short term durability will be the primary objectives. Performance and efficacy data will be collected to evaluate patient quality of life, freedom from heart failure symptoms and other standard heart failure measures including the ability to bridge to other therapies. The development of a fully implantable system will eliminate the need to manage a driveline and will address the risk of exit site infections. Together with smaller and lighter wearable components, the system is designed to provide an improved quality of life for patients. The company believes this system will lead to increased market access to target all Class III HF patients, similar to CRM and neuromodulation devices. In addition, the unique ability to deliver chronic counterpulsation therapy and augment coronary blood flow, may afford a new market opportunity for the treatment of angina and ischemic heart disease where morbidity and mortality remain high in heart failure populations with reduced and preserved ejection fraction.
July 23, 2015
11:57 EDTSSHSunshine Heart U.S. trial update as expected, says Piper Jaffray
Piper Jaffray said Sunshine Heart's announcements that 12 sites for its C-Pulse System study have now been reactivated and that two patients have been enrolled since resuming the trial were in line with the firm's expectations. The firm still thinks Sunshine is on track to accelerate enrollment in the next 12 months and keeps an Overweight rating and $10 price target on its shares.
05:39 EDTSSHSunshine Heart says 12 sites reactivated in Counter HF study for C-Pulse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use